Anti-Ageing Cosmeceuticals Market Set To Grow To $19bn By 2022

14 August 2018
Pharma

Visiongain’ has launched a new pharma report Anti-Ageing Cosmeceuticals 2017-2027:
Anti-wrinkle, Anti-stretch Mark, UV Absorbers, Hair, Topical, Invasive, Acne Therapy, Liposuction, Breast Augmentation, Hair Growth, Eyelid Surgery, Botox, Anti-pigmentation, Abdominoplasty, Other Services

Cosmeceuticals are the future generation of cosmetics and personal care industry as they not only improve appearance but also provide necessary nutrients and drug-like properties to the skin. The core properties of cosmeceuticals may be considered as hybrid of traditional cosmetics and medicines or drugs. Technological advancements have resulted in the launch of advanced and more value-added anti-ageing products in the market.

The lead analyst of the report commented “The growth in per capita disposable income, increasing baby boomer population and rising demand in anti-ageing products due to pollution and fluctuating climatic conditions have boosted the growth of anti-ageing cosmeceuticals market. Furthermore, advertisement and promotional activities from companies have strongly influenced the purchasing power and behaviours of consumers.”

Leading companies featured in the report include Allergan PLC, Avon Products Inc.
Beiersdorf AG, Chanel International B.V., Christian Dior SE, Johnson & Johnson, L'ORÉAL S.A., PROCTER & GAMBLE, Revlon Inc., Unilever PLC.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever